Estimating rates of true high-grade disease in the prostate cancer prevention trial

Cancer Prevention Research
Paul PinskyLeslie Ford

Abstract

The Prostate Cancer Prevention Trial (PCPT) showed a decreased prostate cancer rate but an increased rate of high Gleason grade disease on biopsy for finasteride versus placebo. The results from radical prostatectomy (RP) on 25% of the men undergoing RP have recently been reported and suggest that grading artifacts in biopsy Gleason scoring may have occurred. We used a statistical model to extrapolate the RP Gleason results to all men in the PCPT using a missing-at-random assumption. We estimated the rates of true high-grade (Gleason 7-10) and true low-grade disease, where true Gleason grade is what is (or would have been) found on RP. We also estimated misclassification rates on biopsy of true high-grade and low-grade disease. We show that the rate of upgrading of biopsy low-grade disease to high-grade on RP is a function of misclassification rates as well as the ratio of true low-grade to high-grade disease. The estimated relative risks for true low-grade and true high-grade disease for finasteride compared with placebo were 0.61 (95% confidence interval, 0.51-0.71) and 0.84 (95% confidence interval, 0.68-1.05), respectively. The misclassification rate of true high-grade disease (to low-grade disease on biopsy) was significan...Continue Reading

References

Feb 17, 2001·International Journal of Cancer. Journal International Du Cancer·C R King, J P Long
Jun 26, 2003·The New England Journal of Medicine·Ian M ThompsonCharles A Coltman
Jan 13, 2006·The Journal of Urology·Girish S KulkarniNeil E Fleshner
Sep 13, 2007·Journal of the National Cancer Institute·M Scott LuciaIan M Thompson

❮ Previous
Next ❯

Citations

Jan 12, 2011·Journal of General Internal Medicine·Richard M HoffmanMichael J Barry
Apr 2, 2010·The New England Journal of Medicine·Gerald L AndrioleUNKNOWN REDUCE Study Group
Feb 23, 2010·Biostatistics·Stuart G BakerBarnett S Kramer
Dec 15, 2010·Cancer Prevention Research·Phyllis J GoodmanScott M Lippman
Nov 10, 2013·PloS One·Alexander B Opoku-AcheampongBrian L Lindshield
May 27, 2011·Acta Oncologica·Roger S Rittmaster
Jun 29, 2013·Seminars in Oncology·Gurdarshan S SandhuGerald L Andriole
Nov 30, 2012·Urologic Oncology·Kenneth G Nepple, Gerald L Andriole
Oct 5, 2010·The Journal of Steroid Biochemistry and Molecular Biology·Lucy J Schmidt, Donald J Tindall
Jun 16, 2009·The Journal of Urology·Ian M ThompsonEric A Klein
Feb 10, 2009·European Urology·Roger S RittmasterIan M Thompson
Feb 10, 2009·European Urology·Marcelo Orvieto, Scott Eggener
Nov 26, 2008·Journal of Cataract and Refractive Surgery·David F ChangUNKNOWN ASCRS Cataract Clinical Committee
Aug 28, 2010·BJU International·Roger S KirbyJohn M Fitzpatrick
Oct 15, 2013·Statistics in Medicine·Lurdes Y T InoueRuth Etzioni
Feb 16, 2010·The Urologic Clinics of North America·Andrew J StephensonEric A Klein
Jan 26, 2016·International Journal of Cancer. Journal International Du Cancer·Teemu J MurtolaAnssi Auvinen
Mar 20, 2013·Circulation·Meir Stampfer, Jaquelyn L Jahn
Mar 11, 2010·Current Opinion in Urology·Seth A Strope, Gerald L Andriole
Oct 12, 2010·Nature Reviews. Urology·Peter H Gann
Feb 28, 2009·Nature Reviews. Drug Discovery·William N WilliamScott M Lippman
Feb 18, 2011·Nature Reviews. Cancer·Ki Won LeeZigang Dong
Jun 19, 2009·Nature Reviews. Cancer·Ann M Bode, Zigang Dong
May 27, 2009·Prostate Cancer and Prostatic Diseases·C G RoehrbornA Benedict
Mar 26, 2009·Current Opinion in Urology·Amanda Beth Reed, Dipen J Parekh
Sep 10, 2014·Oncology Letters·John M Lacy, Natasha Kyprianou
Jan 1, 2012·American Society of Clinical Oncology Educational Book·Youssef S Tanagho, Gerald L Andriole
Mar 17, 2018·Journal of the National Cancer Institute·Anna WallerstedtMartin Eklund
Oct 15, 2010·Expert Review of Anticancer Therapy·Jeri Kim
Oct 19, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Steven B Zeliadt, Scott D Ramsey
Jun 6, 2009·Cancer Prevention Research·Scott M Lippman
Jan 14, 2009·Cancer Prevention Research·Christopher J Logothetis, Paul F Schellhammer
Jun 6, 2009·Cancer Prevention Research·Jin Li, Jeri Kim
Jul 9, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher S ElliottJoseph C Presti
Aug 12, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Robert J HamiltonLinda S Kinsinger
Jun 6, 2009·Cancer Research·Scott M Lippman, Ernest T Hawk
May 23, 2013·Bulletin du cancer·François EisingerOlivier Cussenot
Jan 11, 2019·The Annals of Applied Statistics·Jane M LangeRuth Etzioni

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.